Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance in BRCA-mutated relapsed ovarian cancer
CTR20150026Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Started Jan 2015; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20150026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150026.